Actively Recruiting
Evaluation of the Cryocheck HexLA Integrated TCA for the Detection of Lupus Anticoagulant
Led by University Hospital, Strasbourg, France · Updated on 2026-01-02
200
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lupus anticoagulant (LA) testing is performed using two screening tests: activated partial thromboplastin time (APTT) and diluted Russell's viper venom time. If one of the screening tests is positive, a confirmation test based on the same principle is performed. The HUS Hematology Laboratory uses an integrated APTT for LA testing, consisting of a screening reagent: Cephen LS, and a confirmation reagent: Cephen (Hyphen Biomed). The aim of this study is to determine whether another integrated activated partial thromboplastin time (APTT) test, Cryocheck HexLA, offers better performance than Cephen LS/Cephen, both in terms of sensitivity to lupus anticoagulant (LA) and susceptibility to interference from anticoagulant treatments.
CONDITIONS
Official Title
Evaluation of the Cryocheck HexLA Integrated TCA for the Detection of Lupus Anticoagulant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient of legal age (≥ 18 years)
- Sample sent to the HUS Hematology Laboratory and analyzed for LA detection as part of routine care.
You will not qualify if you...
- Insufficient sample volume
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Laboratoire d'Hématologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
A
Agathe HERB, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here